

FREE BETA-SUBUNIT OF HUMAN CHORIONIC GONADOTROPIN (Free β -hCG) ENZYME IMMUNOASSAY TEST KIT Catalog Number: BC-1023



BioCheck, Inc.
323 Vintage Park Drive
Foster City, CA 94404

Enzyme Immunoassay for the determination of Free Beta-Subunit of Human Chorionic Gonadotropin (Free β -hCG) in Human Serum

FOR RESEARCH USE ONLY

Store at 2 to 8°C.

PROPRIETARY AND COMMON NAMES

BioCheck Free β -hCG Enzyme Immunoassay

INTENDED USE

For the quantitative determination of free beta subunit of human chorionic gonadotropin (free β -hCG) concentration in human serum.

INTRODUCTION

Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone normally produced by placenta during pregnancy. The hormone is present in blood and urine around seven to thirteen days following implantation of the fertilized ovum. Structurally intact hCG molecules consist of two non-covalently linked polypeptide subunits, the alpha and beta chain subunits. Measurement of intact hCG and of the alpha subunit of hCG appears to give similar results in blood and urine but not the levels of beta subunit. In the normal second-trimester maternal sera, the level of intact hCG range from 20,000 mIU/ml to 50,000 mIU/ml (1 ng = 15 mIU). In contrast, the levels of either free α - or free β -hCG are on average one half of 1% of hCG levels. hCG and the free subunits appear not to be useful as serological markers for nontrophoblastic tumors; however, the absolute increase of β -hCG level in choriocarcinoma patients clearly differentiates it from normal pregnancy.

PRINCIPLE OF THE TEST

The free β -hCG ELISA test is based on the principle of a solid phase enzyme-linked immunosorbent assay.¹² The assay system utilizes a unique monoclonal antibody directed against a distinct antigenic determinant on the β -subunit of the hCG molecule. Mouse monoclonal anti- β -hCG antibody is used for solid phase immobilization (on the microtiter wells). A rabbit anti- β -hCG antibody is in the antibody-enzyme (horseradish peroxidase) conjugate solution. The test sample is allowed to react sequentially with the two antibodies, resulting in the β -hCG molecules being sandwiched between the solid phase and enzyme-linked antibodies. After incubation two separate 30 minute incubations at 37 °C, the wells are washed with water to remove unbound labeled antibodies. A solution of TMB Reagent is added and incubated for 20 minutes, resulting in the development of a blue color.

The color development is stopped with the addition of Stop Solution changing the color to yellow. The concentration of β -hCG is directly proportional to the color intensity of the test sample. Absorbance is measured spectrophotometrically at 450 nm.

REAGENTS

Materials provided with the kit:

- Antibody-Coated Wells (1 plate, 96 wells)
Microtiter Wells coated with monoclonal anti- β -hCG
- Reference Standard Set (1.0 ml/vial)
Contains 0, 2.5, 5, 10, 25, and 50 ng/ml of β -hCG in bovine serum with preservatives, lyophilized
- Zero Buffer (13 ml)
Contains tris buffer with preservatives
- Enzyme Conjugate Reagent (18 ml)
Contains β -hCG MoAb conjugated to horseradish peroxidase with preservatives
- TMB Reagent (11 ml)
Contains 3, 3', 5, 5' tetramethylbenzidine (TMB) stabilized in buffer solution
- Stop Solution -1N HCl (11 ml)
Diluted hydrochloric acid

Materials required but not provided:

- Precision pipettes: 50 μ l, 100 μ l, 150 μ l, and 1.0 ml.
- Disposable pipette tips.
- Distilled water.
- Vortex mixer or equivalent.
- Absorbent paper or paper towel.
- Graph paper.
- Microtiter plate reader.

WARNINGS AND PRECAUTIONS

1. CAUTION: This kit contains human material. The source material used for manufacture of this component tested negative for HBsAg, HIV 1/2 and HCV by FDA-approved methods. However, no method can completely assure absence of these agents. Therefore, all human blood products, including serum samples, should be considered potentially infectious. Handling should be as defined by an appropriate national biohazard safety guideline or regulation, where it exists.²⁵
2. Avoid contact with 1N HCl. It may cause skin irritation and burns. If contact occurs, wash with copious amounts of water and seek medical attention if irritation persists.
3. Do not use reagents after expiration date and do not mix or use components from kits with different lot numbers.
4. Replace caps on reagents immediately. Do not switch caps.
5. Do not pipette reagents by mouth.
6. For in vitro diagnostic use.

STORAGE CONDITIONS

1. Store the unopened kit at 2-8°C upon receipt and when it is not in use, until the expiration shown on the kit label. Refer to the package label for the expiration date.
2. Keep microtiter plate in a sealed bag with desiccant to minimize exposure to damp air.

INSTRUMENTATION

A microtiter well reader with a bandwidth of 10 nm or less and an optical density range of 0 to 3 OD or greater at 450 nm wavelength is acceptable for absorbance measurement.

SPECIMEN COLLECTION AND PREPARATION

1. The use of SERUM samples is required for this test.
2. Specimens should be collected using standard venipuncture techniques. Remove serum from the coagulated or packed cells within 60 minutes after collection.
3. Specimens which cannot be assayed within 24 hours of collection should be frozen at -20°C or lower, and will be stable for up to six months.
4. Avoid grossly hemolytic (bright red), lipemic (milky), or turbid samples (after centrifugation).
5. Specimens should not be repeatedly frozen and thawed prior to testing. DO NOT store in "frost free" freezers, which may cause occasional thawing. Specimens which have been frozen, and those which are turbid and/or contain particulate matter, must be centrifuged prior to use.

PROCEDURAL NOTES

1. Pipetting Recommendations (single and multi-channel): Pipetting of all standards, samples, and controls should be completed within 3 minutes.
2. All standards, samples, and controls should be run in duplicate concurrently so that all conditions of testing are the same.
3. It is recommended that the wells be read within 15 minutes following addition of Stop Solution.

REAGENT PREPARATION

1. All reagents should be brought to room temperature (18-25 °C) before use.
2. Reconstitute each lyophilized standard with 1.0 ml distilled water. Allow the reconstituted material to stand for at least 20 minutes and mix gently. Reconstituted standards will be stable for up to 30 days when stored sealed at 2-8 °C.

ASSAY PROCEDURE

1. Secure the desired number of coated wells in the holder.
2. Dispense 50 µl of standards, specimens, and controls into appropriate wells.
3. Dispense 100 µl of Zero Buffer into each well.

4. Thoroughly mix for 30 seconds. It is very important to mix them completely.
5. Incubate at 37 °C for 30 minutes.
6. Remove the incubation mixture by flicking plate contents into a sink.
7. Rinse and flick the microtiter wells 5 times with distilled or deionized water. (Please do not use tap water.)
8. Strike the wells sharply onto absorbent paper or paper towels to remove all residual water droplets.
9. Dispense 150 µl of Enzyme Conjugate Reagent into each well. Gently mix for 10 seconds.
10. Incubate at 37 °C for 30 minutes.
11. Remove the incubation mixture by flicking plate contents into a waste container.
12. Rinse and flick the microtiter wells 5 times with distilled or deionized water. (Please do not use tap water.)
13. Strike the wells sharply onto absorbent paper or paper towels to remove all residual water droplets.
14. Dispense 100 µl of TMB Reagent into each well. Gently mix for 10 seconds.
15. Incubate at room temperature for 20 minutes.
16. Stop the reaction by adding 100 µl of Stop Solution to each well.
17. Gently mix for 30 seconds. ***It is important to make sure that all the blue color changes to yellow color completely.***
18. Read optical density at 450 nm with a microtiter well reader **within 15 minutes.**

QUALITY CONTROL

Good laboratory practice requires that quality control specimens (controls) be run with each calibration curve to verify assay performance. To ensure proper performance, control material should be assayed repeatedly to establish mean values and acceptable ranges.


CALCULATION OF RESULTS

1. Calculate the mean absorbance value (A_{450}) for each set of reference standards, controls and patient samples.
2. Construct a standard curve by plotting the mean absorbance obtained from each reference standard against its concentration in ng/ml on graph paper, with absorbance values on the vertical or Y axis, and concentrations on the horizontal or X axis.
3. Use the mean absorbance values for each specimen to determine the corresponding concentration of β -hCG in ng/ml from the standard curve.

EXAMPLE OF STANDARD CURVE

Results of a typical standard run with optical density readings at 450 nm shown in the Y axis against β -hCG concentrations shown in the X axis. This standard curve is for the purpose of illustration only, and should not be used to calculate unknowns. Each user should obtain his or her own data and standard curve.

β -hCG(ng/ml)	Absorbance (450 nm)
0	0.061
2.5	0.296
5.0	0.498
10.0	0.929
25.0	1.711
50.0	2.613



STANDARDIZATION

For intact hCG, 1 ng is approximately equivalent to 15 mIU (WHO, 1st IRP 75/537). For free β -hCG subunit, since there is no WHO standardization, we tested the free β -hCG against BioCheck's hCG ELISA kit, and found 1 ng of free β -hCG equals to 0.1 mIU in terms of hCG immunological activity.

EXPECTED VALUES

1. hCG and Free β -hCG Subunit Levels in Normal Pregnancy

A logarithmic increase in the serum concentration of hCG was observed from 5-8 weeks of gestation (2,600 ng/ml to 33,000 ng/ml) as defined by last menstrual period; thereafter, hCG values decreased. Similarly, free β -hCG levels increased rapidly to reach maximum levels (~60 ng/ml) at 8-9 weeks of pregnancy, followed by a gradual decline during the next 11-12 weeks of gestation.

At 5 weeks of gestation, the ratio of free β -hCG to intact hCG is approximately 1.0 % (w/w). Thereafter, this ratio remains remarkably constant over 22 weeks of gestation (~ 0.5 % w/w).

2. hCG and Free Subunits Levels in Gestational Choriocarcinoma

Free α and free β -subunits and hCG levels were measured in five patients with untreated gestational choriocarcinoma. The concentrations in serum are shown in the following table:

Patient Number	hCG (ng/ml)	α -hCG (ng/ml)	β -hCG (ng/ml)
1	210,000	112	8,000
2	22,195	20	1,300
3	6,840	1	232
4	36,000	44	3,900
5	4,200	2	350

The levels of free α -hCG were low, ranging from 1-112 ng/ml, whereas hCG levels ranged from 4,200 to 210,000 ng/ml (1 ng \approx 15 mIU). In contrast, free β -hCG concentrations were found to be markedly elevated in choriocarcinoma.

3. Ectopic Production of hCG and Free Subunits by Nontrophoblastic Tumors

The following table shows results obtained in various tumors and healthy and benign disease controls.

Measurement of hCG, α -hCG, and β -hCG serum levels in nontrophoblastic tumors, benign disease, and healthy controls

Tumor type	No. of samples	hCG (ng/ml)	α -hCG (ng/ml)	β -hCG (ng/ml)
Cervix	20	0	1 (1.6) ^a	1 (0.65)
Corpus uterus	20	0	0	0
Gastric	20	0	0	1 (1.5)
Pancreatic	20	0	1 (16.0)	2 (0.8, 3.1)
Colon	20	0	0	0
Lung	20	0	1 (90.0)	1 (0.7)
Ovarian	20	0	1 (1.8)	0
Prostate	20	0	1 (1.6)	0
Other digestive tract tumor	18	0	0	0
Total [%]	178	0	5 [3]	5 [3]
Benign disease controls	61	0	1 (1.6)	0
Healthy controls	50	0	0	0
Total [%]	111	0	1 [1]	0

^a The number in parentheses represents the measured value in ng/ml.

The cut-off values for positive results are 1.5 ng/ml for hCG and α -hCG and 0.4 ng/ml for β -hCG.

When compared with healthy control values, all nontrophoblastic cancer patients had hCG concentration within the normal range (~ 0.9 ng/ml). Free subunits were elevated in 10 of 178 patients. It is noteworthy that α -hCG levels in two patients (pancreatic and lung tumors) were relatively high (16 and 90 ng/ml, respectively), whereas the maximum concentration of free β -hCG was only 3.1 ng/ml (pancreatic tumor).

PERFORMANCE CHARACTERISTICS

1. Accuracy

A statistical study using patient samples demonstrated good correlation of results with the commercially available kits as shown below:

Comparisons between BioCheck free β -hCG ELISA and Truquant BR™ CA 27.29 RIA kits provide the following data:

N = 142
 Correlation coefficient = 0.998
 Slope = 1.055
 Intercept = 14.48
 BioCheck Mean = 197 U/mL
 Truquant BR Mean = 222 U/mL

2. Sensitivity

The minimal detectable concentration of free β -hCG by this assay is estimated to be 0.25 ng/mL.

3. Precision

a. Intra-Assay Precision

Within-run precision was determined by replicate determinations of three different control sera in one assay. Within-assay variability is shown below:

Serum Sample	1	2	3
Number of Replicates	24	24	24
Mean free β -hCG (ng/mL)	2.8	14	36
Standard Deviation	0.11	0.4	1.5
Coefficient of Variation (%)	3.7	2.6	4.3

b. Inter-Assay Precision

Between-run precision was determined by replicate measurements of three different control sera in several different assays. Between-assay variability is shown below:

Serum Sample	1	2	3
Number of Replicates	20	20	20
Mean free β -hCG (ng/mL)	3.0	17	37
Standard Deviation	0.10	0.7	0.7
Coefficient of Variation (%)	3.4	4.0	2.0

4. Recovery and Linearity Studies

a. Recovery

Various patient serum samples of known free β -hCG levels were mixed and assayed in duplicate. The average recovery was 96.7%.

	Expected Concentration (ng/ml)	Observed Concentration (ng/ml)	% Recovery
1.	41.22	39.68	96.3
2.	40.61	37.73	92.9

3.	15.07	15.58	103.4
4.	17.44	17.06	97.8
5.	3.389	3.258	96.1
6.	3.352	2.986	89.1
7.	0.493	0.478	97.1
8.	0.436	0.441	101.1
			Average Recovery = 96.7%

b. Linearity

Four patient samples were serially diluted with the zero standard in a linearity study. The average recovery was 111.3%.

#	Dilution	Expected Conc. (ng/mL)	Observed Conc. (ng/mL)	% Recovery
1.	Undiluted	----	34.54	----
	1:2	17.27	19.18	111.1
	1:4	8.634	8.822	102.2
	1:8	4.317	4.701	108.9
	1:16	2.159	2.398	111.1
Mean = 108.3 %				
2.	Undiluted	----	47.81	----
	1:2	23.91	23.98	100.3
	1:4	11.95	13.69	114.5
	1:8	5.977	7.538	126.1
	1:16	2.988	3.872	129.6
Mean = 117.6 %				
3.	Undiluted	----	42.09	----
	1:2	21.05	22.70	107.9
	1:4	10.52	10.50	99.8
	1:8	5.262	5.519	104.9
	1:16	2.631	2.930	111.4
Mean = 106.0%				
4.	Undiluted	----	35.48	----
	1:2	17.74	20.27	114.3
	1:4	8.869	9.424	106.3
	1:8	4.435	5.200	117.3
	1:16	2.217	2.554	115.2
Mean = 113.3%				

5. Specificity

The following substances were tested for cross-reactivity:

Analyte Tested	Concentration (ng/mL)	Produced Intensity Equivalent to Free β -hCG (ng/mL)	% Cross Reactivity
α -hCG	1000	1.0	0.10
	500	0.69	0.14
	250	0.33	0.13
	100	0	N/A
	50	0	N/A
	25	0	N/A
	10	0	N/A
	5	0	N/A

Limitations of the Procedure

1. Reliable and reproducible results will be obtained when the assay procedure is carried out with a complete understanding of the package insert instructions and will adhere to good laboratory practice.
2. The wash procedure is critical. Insufficient washing will result in poor precision and falsely elevated absorbance readings.
3. Serum samples demonstrating gross lipemia, gross hemolysis, or turbidity should not be used with this test.
4. The results obtained from the use of this kit should be used only as an adjunct to other diagnostic procedures and information available to the physician.

REFERENCES

- ¹ Engall, E., Enzyme immunoassay ELISA and EMIT. In: Van Vunakis, H. and Langone, J.J. (eds.), *Methods in Enzymology*, Academic Press, New York, 1980; 70: 419-439.
- ² Densem, J., and Wald, N.J., The stability of blood samples for the measurement of the free β subunit of chorionic gonadotrophin. *Prenat. Diagn.*, 1995; 15: 94-95.
- ³ Ozturk, M., Berkowitz, R., Goldstein, D., Bellet, D., Wands, J. R., Differential production of human chorionic gonadotropin and free subunits in gestational trophoblastic disease. *Am. J. Obstet. Gynecol.*, 1988; 158:193-198.
- ⁴ Hay, D.L., Placental histology and the production of human choriogonadotrophin and its subunits in pregnancy. *Br. J. Obstet. Gynaecol.*, 1988; 95: 1268-1275.
- ⁵ Ozturk, M., Bellet, D., Manil, L., et al., Physiological studies of human chorionic gonadotropin (hCG), ohCG, and β hCG as measured by specific monoclonal immunoradiometric assays. *Endocrinology*, 1987; 120: 549-558.
- ⁶ Cole, L.A., Hartle, R.J., Laferla, J.J., et al., Detection of the free beta subunit of human chorionic gonadotropin (hCG) in cultures of normal and malignant trophoblast cells, pregnancy sera, and sera of patients with choriocarcinoma. *Endocrinology*, 1983; 113:1176-1178.
- ⁷ Gaspard, U.J., Reuter, A.M., Deville, J-L, et al., Serum concentration of human chorionic gonadotropin and its alpha and beta subunits. *Clin. Endocrinol. (OXF)*, 1980; 13: 319-329.
- ⁸ Tietz, N.W. ed., *Clinical Guide to Laboratory Tests*, 3rd Edition, W.B. Saunders, Co., Philadelphia, 1995: 134-135.

TECHNICAL CONSULTATION

Call or Write: **BioCheck, Inc.**
Vintage Park Drive
Foster City, CA 94404
Tel: (650) 573-1968 Fax: (650) 573-1969

072507